Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
22 hedge funds and large institutions have $5.23M invested in Soleno Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 13 reducing their positions, and 21 closing their positions.
54% more call options, than puts
Call options by funds: $37K | Put options by funds: $24K
35.93% more ownership
Funds ownership: 2.71% → 38.64% (+36%)
41% less capital invested
Capital invested by funds: $8.8M → $5.23M (-$3.57M)
45% less funds holding
Funds holding: 40 → 22 (-18)
77% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 13
86% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Clayton Partners
Berkeley,
California
|
+$243K |
| 2 |
JGC
J. Goldman & Co
New York
|
+$110K |
| 3 |
Renaissance Technologies
New York
|
+$20.2K |
| 4 |
Morgan Stanley
New York
|
+$1.58K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$394K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$60.7K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$55K |
| 4 |
Two Sigma Advisers
New York
|
-$43K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$35.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
26
Virtu Financial
New York
| – | -$12K | -4,505 | Closed |
|
|
AL
27
Aspiriant LLC
Los Angeles,
California
| – | -$11K | -3,820 | Closed |
|
28
UBS Group
Zurich,
Switzerland
| – | -$10K | -3,646 | Closed |
|
|
HF
29
HRT Financial
New York
| – | -$8K | -3,182 | Closed |
|
30
Millennium Management
New York
| – | -$9K | -3,088 | Closed |
|
31
Bank of New York Mellon
New York
| – | -$8K | -2,818 | Closed |
|
|
OBWG
32
Onyx Bridge Wealth Group
Tarrytown,
New York
| – | -$4K | -1,333 | Closed |
|
33
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$2.73K | -1,123 | Closed |
|
|
TSS
34
Two Sigma Securities
New York
| – | -$2K | -848 | Closed |
|
|
APP
35
Avantax Planning Partners
Dubuque,
Iowa
| – | -$2K | -713 | Closed |
|
|
LWMG
36
Levy Wealth Management Group
Philadelphia,
Pennsylvania
| – | -$2K | -667 | Closed |
|
37
Wells Fargo
San Francisco,
California
| – | -$15 | -6 | -14% |
|
38
Osaic Holdings
Scottsdale,
Arizona
| – | -$10 | -4 | -5% |
|
39
BlackRock
New York
| – | -$5 | -2 | -0.6% |
|
40
JP Morgan Chase
New York
| – | +$10 | +4 | +67% |
|
SLNO Hedge Fund Activity: Q3 2022 in Review
22 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2022, worth a combined $5.23M — down 41% from $8.8M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of SLNO and 3 opened new positions — a net loss of 18 holders — while 13 trimmed existing stakes and 3 added.
The largest buyer was Clayton Partners, opening a new position worth an estimated $243K. The largest seller was Oracle Investment Management, exiting entirely with an estimated $394K sold.
- 22 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2022, down from 40 in Q2 2022.
- Funds reported $5.23M of Soleno Therapeutics stock for Q3 2022, down 41% quarter-over-quarter.
- 3 funds opened new Soleno Therapeutics positions in Q3 2022 and 21 closed out, a net change of -18 holders.
- The largest Soleno Therapeutics buyer in Q3 2022 was Clayton Partners, an estimated $243K added.
- The largest Soleno Therapeutics seller in Q3 2022 was Oracle Investment Management, an estimated $394K sold.
Based on aggregated 13F filings for Q3 2022.